This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Subscribe To Our Newsletter & Stay Updated